Sunday, May 26, 2013 Last update: Yesterday, 8:34 AM
Company Tech News as it Breaks
Trade Events
Targacept, Inc.
News articles for Targacept, Inc.:
Tuesday, May 7, 2013
- Targacept Reports First Quarter 2013 Financial ResultsTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended ... read more
Tuesday, April 30, 2013
- Targacept to Report First Quarter 2013 Financial Results on May 7, 2013Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that it will report financial results for the first quarter of 2013 on the ... read more
Monday, April 29, 2013
- Targacept Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer’s DiseaseTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that it has completed recruitment of patients in ... read more
Monday, April 22, 2013
- Targacept Announces Participation in Upcoming ConferencesTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to ... read more
Thursday, April 18, 2013
- Targacept Completes Recruitment in Phase 2b Schizophrenia Trial of TC-5619Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that it has completed recruitment of patients in ... read more
Monday, March 18, 2013
- Targacept Announces Changes to Board of Directors and ManagementTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced the following changes to its Board of Directors: ... read more
Tuesday, March 5, 2013
- Targacept and AstraZeneca Amend CollaborationTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that its collaboration with AstraZeneca has been restructured. Under the new ... read more
Tuesday, February 26, 2013
- Targacept to Present at the Cowen and Company 33rd Annual Health Care ConferenceTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to ... read more
Monday, February 4, 2013
- Targacept to Present at the 15th Annual BIO CEO & Investor ConferenceTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to ... read more
Tuesday, November 27, 2012
- Targacept to Present at the 2012 Deutsche Bank dbAccess BioFESTTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that members of its executive management are scheduled to present at the 2012 ... read more